The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy

被引:0
|
作者
Lu Chen
Jingjuan Huang
Weihua Wu
Shengjun Ta
Xiaoyi Xie
机构
[1] Shanghai Chest Hospital,Department of Ultrasound
[2] Shanghai Jiao Tong University,Department of Cardiology
[3] Shanghai Chest Hospital,Department of Ultrasound
[4] Shanghai Jiao Tong University,undefined
[5] Yan’an People’s Hospital,undefined
来源
The International Journal of Cardiovascular Imaging | 2019年 / 35卷
关键词
Right ventricle; Strain; Chemoradiotherapy; Non-small cell lung cancer;
D O I
暂无
中图分类号
学科分类号
摘要
Right ventricular (RV) impairment after cancer therapy-related cardiotoxicity and its prognostic implications in lung cancer have not been examined. The present research sought to evaluate RV structure, function, and mechanics in stage III non-small-cell lung cancer (NSCLC) before and after concurrent chemoradiotherapy (CCRT), and to explore the associations between RV impairments, radiation dose, and all-cause mortality. This prospective investigation included 128 inoperable NSCLC patients who were scheduled to receive CCRT. Echocardiographic examination and strain evaluation was performed at baseline and 6 months post-CCRT in all participants. Conventional RV dimensions revealed no significant changes post-CCRT. However, a reduction in RV free wall strain (RV-fwLS) was observed at 6 months post-CCRT (− 28.3 ± 4.6% vs. − 25.5 ± 4.8%, P < 0.001). The same was revealed for global RV longitudinal strain (RV-GLS) (− 23.4 ± 2.9% vs. − 20.2 ± 3.4%, P < 0.001). Pearson correlation showed that RV radiation mean dose was related with the percentage change in RV-fwLS (r = 0.303, P = 0.001) and RV-GLS (r = 0.284, P = 0.002). In multivariable analysis, the percentage change in RV-fwLS was an independent predictor of all-cause mortality (HR 1.296, 95% CI 1.202–1.428, P < 0.001). RV longitudinal strain is deteriorated at 6 months post-CCRT. The RV mechanics deterioration was associated with radiation dose and affected the long-term outcome of stage III NSCLC patients treated with CCRT.
引用
收藏
页码:1009 / 1017
页数:8
相关论文
共 50 条
  • [31] Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy
    Xiaojuan Yu
    Jin Li
    Xiaoming Zhong
    Jingdong He
    BMC Cancer, 15
  • [32] Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy
    Yu, Xiaojuan
    Li, Jin
    Zhong, Xiaoming
    He, Jingdong
    BMC CANCER, 2015, 15 : 1
  • [33] Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study
    Takase, Naoto
    Hattori, Yoshihiro
    Kiriu, Tatsunori
    Itoh, Shouichi
    Kawa, Yoshitaka
    Yamamoto, Masatsugu
    Urata, Yoshiko
    Shimada, Temiko
    Tsujino, Kayoko
    Soejima, Toshinori
    Negoro, Shunichi
    Satouchi, Miyako
    RESPIRATORY INVESTIGATION, 2016, 54 (05) : 334 - 340
  • [34] Predictive value of primary tumor volume change during concurrent chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer
    Lee, Hye In
    Choi, Eun Kyung
    Kim, Su Ssan
    Shin, Young Seob
    Park, Jae Won
    Song, Si Yeol
    RADIOTHERAPY AND ONCOLOGY, 2024, 198
  • [35] Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer
    Nan Jiang
    Xiao-Cen Chen
    Yue Zhao
    Supportive Care in Cancer, 2013, 21 : 785 - 791
  • [36] Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer
    Jiang, Nan
    Chen, Xiao-Cen
    Zhao, Yue
    SUPPORTIVE CARE IN CANCER, 2013, 21 (03) : 785 - 791
  • [37] The Impact of Radiation Pneumonitis on Prognosis of Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy
    Akita, T.
    Baba, K.
    Tanaka, H.
    Fujioka, I.
    Suzuki, S.
    Tabe, C.
    Shiratori, T.
    Ishioka, Y.
    Itoga, M.
    Taima, K.
    Yokouchi, J.
    Hasegawa, Y.
    Takanashi, S.
    Tasaka, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S636 - S636
  • [38] What is the role for surgery in patients with stage III non-small cell lung cancer?
    Vandenbroucke, Elke
    De Ryck, Frederic
    Surmont, Veerle
    van Meerbeeck, Jan P.
    CURRENT OPINION IN PULMONARY MEDICINE, 2009, 15 (04) : 295 - 302
  • [39] Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study
    Takeya Sugimoto
    Daichi Fujimoto
    Yuki Sato
    Motohiro Tamiya
    Takashi Yokoi
    Akihiro Tamiya
    Shunichiro Iwasawa
    Akito Hata
    Junji Uchida
    Yasushi Fukuda
    Satoshi Hara
    Masaki Kanazu
    Katsuya Hirano
    Masaki Kokubo
    Nobuyuki Yamamoto
    Investigational New Drugs, 2021, 39 : 853 - 859
  • [40] Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study
    Sugimoto, Takeya
    Fujimoto, Daichi
    Sato, Yuki
    Tamiya, Motohiro
    Yokoi, Takashi
    Tamiya, Akihiro
    Iwasawa, Shunichiro
    Hata, Akito
    Uchida, Junji
    Fukuda, Yasushi
    Hara, Satoshi
    Kanazu, Masaki
    Hirano, Katsuya
    Kokubo, Masaki
    Yamamoto, Nobuyuki
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (03) : 853 - 859